NOD9 Inhibitors

NOD9 Inhibitors are compounds that, while not directly inhibiting NOD9 (NLRX1), can influence its activity indirectly. These compounds primarily affect cellular stress responses or the innate immune response, thereby influencing the function of NLRX1. For instance, Cyclosporine A and FK506 are immunosuppressants that inhibit the calcineurin pathway. As NLRX1 plays a role in the innate immune response, these compounds can indirectly inhibit NLRX1. Conversely, compounds like PD98059, SP600125, SB203580, BAY 11-7082, LY294002, Wortmannin, and Rapamycin inhibit various parts of the MAPK and PI3K/AKT/mTOR pathways. Given NLRX1's role in modulating these pathways, these compounds can trigger its inhibition. Other compounds like Mdivi-1, 2-Deoxy-D-glucose, and Z-VAD-FMK disrupt mitochondrial function, inhibit glycolysis, or inhibit apoptosis, respectively.